MX2020011471A - R-fadrozol para usar en el tratamiento de aldosteronismo. - Google Patents

R-fadrozol para usar en el tratamiento de aldosteronismo.

Info

Publication number
MX2020011471A
MX2020011471A MX2020011471A MX2020011471A MX2020011471A MX 2020011471 A MX2020011471 A MX 2020011471A MX 2020011471 A MX2020011471 A MX 2020011471A MX 2020011471 A MX2020011471 A MX 2020011471A MX 2020011471 A MX2020011471 A MX 2020011471A
Authority
MX
Mexico
Prior art keywords
compound
disorder
disease
composition
pharmaceutical composition
Prior art date
Application number
MX2020011471A
Other languages
English (en)
Inventor
Christoph Schumacher
Ronald Edward Steele
Original Assignee
Damian Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Damian Pharma Ag filed Critical Damian Pharma Ag
Publication of MX2020011471A publication Critical patent/MX2020011471A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a una composición para su uso en el tratamiento de una enfermedad o trastorno, en donde dicha enfermedad o trastorno es preferentemente una enfermedad o trastorno en donde la sobreexposición de aldosterona contribuye a los síntomas de dicha enfermedad o trastorno, dicha composición comprende un compuesto que es (R)-(+)-5-(p-cianofenil)-5,6,7,8-tet rahidroimidazo[1,5- a]piridina o una sal farmacéuticamente aceptable de este, en donde preferentemente dicho compuesto es el dihidrogenofosfato de (R)-(+)-5-(p-cianofenil)-5,6,7,8-tetrahidroi midazolio[1,5-a]piridina, y en donde dicho compuesto tiene un exceso enantiomérico (ee) de la forma (R) superior o igual al 97 %, y en donde dicha composición se administra una vez al día a un sujeto que lo necesite. La invención se refiere además a una composición farmacéutica que comprende una dosis diaria de dicho compuesto en una forma de dosificación de unidad fija y una combinación que comprende (i) dicha composición farmacéutica o dicho compuesto; e (ii) instrucciones para la administración de dicha composición farmacéutica o dicho compuesto una vez al día.
MX2020011471A 2018-05-03 2019-05-02 R-fadrozol para usar en el tratamiento de aldosteronismo. MX2020011471A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862666412P 2018-05-03 2018-05-03
EP18176345 2018-06-06
PCT/EP2019/061283 WO2019211394A1 (en) 2018-05-03 2019-05-02 R-fadrozole for use in the treatment of aldostonerism

Publications (1)

Publication Number Publication Date
MX2020011471A true MX2020011471A (es) 2020-12-07

Family

ID=66334511

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011471A MX2020011471A (es) 2018-05-03 2019-05-02 R-fadrozol para usar en el tratamiento de aldosteronismo.

Country Status (14)

Country Link
US (1) US11992479B2 (es)
EP (1) EP3787623A1 (es)
JP (1) JP7470050B2 (es)
KR (1) KR20210005684A (es)
CN (1) CN112055590A (es)
AU (1) AU2019262310A1 (es)
BR (1) BR112020022173A2 (es)
CA (1) CA3097281A1 (es)
CL (1) CL2020002803A1 (es)
MX (1) MX2020011471A (es)
PH (1) PH12020551654A1 (es)
SG (1) SG11202010906XA (es)
WO (1) WO2019211394A1 (es)
ZA (1) ZA202006886B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024079324A1 (en) 2022-10-14 2024-04-18 Damian Pharma Ag Once daily aldosterone synthase inhibitor (r)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[l,5-a]pyridine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617307A (en) 1984-06-20 1986-10-14 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US5428160A (en) 1982-12-21 1995-06-27 Ciba-Geigy Corporation Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives
US4889861A (en) 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4728645A (en) 1982-12-21 1988-03-01 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors
US5057521A (en) 1988-10-26 1991-10-15 Ciba-Geigy Corporation Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism
MTP1076B (en) 1990-01-12 1991-09-30 Ciba Geigy Ag Hemihydrate
NZ534086A (en) * 2000-04-12 2006-08-31 Novartis Ag Use of an aldosterone synthase inhibitor in combination with an angiotensin I receptor antagonist or an angiotensin I receptor antagonist plus a diuretic to treat various conditions
EP1282410A2 (en) 2000-04-12 2003-02-12 Novartis AG Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists
WO2005099695A1 (en) * 2004-04-19 2005-10-27 Novartis Ag Drug delivery systems for the prevention and treatment of vascular diseases
DE102004035322A1 (de) 2004-07-21 2006-02-16 Universität des Saarlandes Selektive Hemmstoffe humaner Corticoidsynthasen
GT200600381A (es) 2005-08-25 2007-03-28 Compuestos organicos
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
SI2804863T1 (sl) 2012-01-17 2016-05-31 Novartis Ag Nove oblike in soli zaviralca sinteze ali aromataze dihidropropirolo(1,2-c)imidazolil aldosterona
JP6731136B2 (ja) 2014-07-07 2020-07-29 レコルダティ アーゲー 医薬製剤
WO2018078049A1 (en) * 2016-10-27 2018-05-03 Damian Pharma Ag Aldosterone synthase inhibitor
EP3532056A1 (en) 2016-10-27 2019-09-04 Damian Pharma AG Aldosterone synthase inhibitor

Also Published As

Publication number Publication date
CN112055590A (zh) 2020-12-08
JP7470050B2 (ja) 2024-04-17
SG11202010906XA (en) 2020-12-30
AU2019262310A1 (en) 2020-11-12
EP3787623A1 (en) 2021-03-10
US11992479B2 (en) 2024-05-28
ZA202006886B (en) 2022-07-27
US20210169861A1 (en) 2021-06-10
CA3097281A1 (en) 2019-11-07
BR112020022173A2 (pt) 2021-02-02
PH12020551654A1 (en) 2021-07-26
JP2021522289A (ja) 2021-08-30
CL2020002803A1 (es) 2021-03-12
KR20210005684A (ko) 2021-01-14
WO2019211394A1 (en) 2019-11-07

Similar Documents

Publication Publication Date Title
MX2007005570A (es) Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y manejo de padecimientos parasiticos.
MXPA05012155A (es) Metodos y composiciones que utilizan compuestos inmunomoduladores para el tratamiento y manejo de canceres y otras enfermedades.
TW200500355A (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
WO2003097052A3 (en) Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases
MX2021009199A (es) Conjugado de farmaco de dos ligandos y uso del mismo.
NZ714963A (en) Compositions and methods for treating anemia
WO2007149283B1 (en) Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload
NZ605469A (en) Nalbuphine-based formulations and uses thereof
MX344476B (es) Metodos de tratar trastornos pulmonares con formulaciones de amikacina liposomal.
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
RU2013123646A (ru) Комбинированная композиция
TW200501945A (en) Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
WO2005046593A3 (en) Methods and compositions using thalidomide for the treatment and management of cancers and other diseases.
MX2019001596A (es) Uso y dosificacion de agentes terapeuticos para endometriosis.
JP2016505050A5 (es)
PH12020551654A1 (en) R-fadrozole for use in the treatment of aldostonerism
MX2015009546A (es) Dosificacion aumentada de efavirenz para el tratamiento de cancer.
FI3493812T3 (fi) Imetelstaatin ja venetoklaksin yhdistelmiä akuutin myelooisen leukemian hoitoa varten
SG163500A1 (en) Composition and method for improved bioavailiability and enhanced brain delivery of 5,5-diphenyl barbituric acid
MY193963A (en) Composition for treating joint diseases and kit containing same
MX2022006934A (es) Inhibidor de aldosterona sintasa.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
RU2018130097A (ru) Лечение экземы кистей
MX2023007150A (es) Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos.